← Back to Search
The Therapeutic Potential Of Nanoscale Sphingolipid Technologies.
Jody L Hankins, Ushma A. Doshi, Jeremy K. Haakenson, Megan M Young, Brian M Barth, M. Kester
Published 2013 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Nanotechnologies, while small in size, widen the scope of drug delivery options for compounds with problematic pharmacokinetics, such as bioactive sphingolipids. We describe the development of historical sphingolipid nanotechnologies, such as nanoliposomes, and project future uses for a broad repertoire of nanoscale sphingolipid therapy formulations. In particular, we describe sphingo-nanotherapies for treatment of cancer, inflammatory disease, and cardiovascular disease. We conclude with a discussion of the challenges associated with regulatory approval, scale-up, and development of these nanotechnology therapies for clinical applications.
This paper references
Development of small-molecule inhibitors of sphingosine-1-phosphate signaling.
Yvette Edmonds (2011)
Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel.
H. Cho (2011)
Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia.
X. Liu (2010)
Propagation of undifferentiated human embryonic stem cells with nano-liposomal ceramide.
U. Salli (2009)
Ceramide and Ceramide 1-Phosphate Are Negative Regulators of TNF-α Production Induced by Lipopolysaccharide
S. Jozefowski (2010)
A Phase II Study of Topical Ceramides for Cutaneous Breast Cancer
A. Jatoi (2004)
Release of trapped marker from liposomes by the action of purified complement components.
J. Haxby (1969)
Encapsula - tion of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery
TT Morgan (2008)
Studies on the Role of Acid Sphingomyelinase and Ceramide in the Regulation of Tumor Necrosis Factor α (TNFα)-converting Enzyme Activity and TNFα Secretion in Macrophages*
K. A. Rozenova (2010)
Ceramide-Coated Balloon Catheters Limit Neointimal Hyperplasia After Stretch Injury in Carotid Arteries
R. Charles (2000)
GD2‐mediated melanoma cell targeting and cytotoxicity of liposome‐entrapped fenretinide
G. Pagnan (1999)
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists
S. Mandala (2002)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M. Matloubian (2004)
WITHDRAWN: Ceramide kinase regulates the production of TNFα via inhibition of TNFα-converting enzyme
Nadia F. Lamour (2011)
Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo.
S. Boddapati (2008)
Use of a novel anti-proliferative compound coated on a biopolymer to mitigate platelet-derived growth factor-induced proliferation in human aortic smooth muscle cells: comparison with sirolimus
Yong-dan Tang (2008)
Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer
Y. Jiang (2011)
Paclitaxel and ceramide co‐administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer
H. Devalapally (2007)
C(6)-Ceramide-Coated Catheters Promote Re-Endothelialization of Stretch-Injured Arteries.
S. M. O'Neill (2008)
Liposomal Delivery Enhances Short-Chain Ceramide-Induced Apoptosis of Breast Cancer Cells
Tom Stover (2003)
Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance
Brian M Barth (2010)
Exogenous Ceramide-1-phosphate Reduces Lipopolysaccharide (LPS)-mediated Cytokine Expression*
Jody L Hankins (2011)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
Diffusion of univalent ions across the lamellae of swollen phospholipids.
A. Bangham (1965)
Sphingosine-1-phosphate signaling in the cardiovascular system.
S. Peters (2007)
Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development
Melissa A. Tran (2008)
Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.
Lilian E van Vlerken (2007)
Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations.
Ankita Desai (2008)
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
A. Klibanov (1990)
The Lipids C2- and C16-Ceramide Form Large Stable Channels
L. Siskind (2000)
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
F. Pastorino (2006)
Immunological properties of engineered nanomaterials
M. Dobrovolskaia (2007)
Ceramide Kinase Regulates the Production of Tumor Necrosis Factor α (TNFα) via Inhibition of TNFα-converting Enzyme*
Nadia F. Lamour (2011)
Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents.
L. Kedderis (1995)
Modulation of cell surface iron transferrin receptors by cellular density and state of activation.
J. Larrick (1979)
Inhibition of corneal inflammation by liposomal delivery of short‐chain, C‐6 ceramide
Y. Sun (2008)
Fate of protein-containing liposomes injected into rats. An approach to the treatment of storage diseases.
G. Gregoriadis (1972)
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors*
V. Brinkmann (2002)
In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia.
Kuan-Boone Tan (2012)
Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells.
M. Kester (2008)
Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
F. Pastorino (2003)
Lipid composition is important for highly efficient target binding and retention of immunoliposomes.
K. Maruyama (1990)
Nanoparticulate alternatives for drug delivery.
James H. Adair (2010)
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation
A. Rahman (2007)
A Phase I Clinical Trial of Safingol in Combination with Cisplatin in Advanced Solid Tumors
M. Dickson (2011)
Ceramide inhibits LPS‐induced production of IL‐5, IL‐10, and IL‐13 from mast cells
N. Chiba (2007)
Rapid Distribution of Liposomal Short-Chain Ceramide in Vitro and in Vivo
Banu S Zolnik (2008)
Complement-mediated lysis of liposomes produced by the reactive lysis procedure.
P. Lachmann (1970)
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
V. Brinkmann (2010)
Effect of lipid-containing, positively charged nanoemulsions on skin hydration, elasticity and erythema--an in vivo study.
E. Yılmaz (2006)
Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes
Alexander Koshkaryev (2012)
Ceramide-based therapeutics for the treatment of cancer.
Brian M Barth (2011)
Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues.
T. Allen (1989)
Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin.
H. Cho (2012)
Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro.
J. A. Shabbits (2003)
High ceramide content liposomes with in vivo antitumor activity.
J. A. Shabbits (2003)
Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug.
Thomas C. Stover (2008)
Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery.
Thomas T. Morgan (2008)
Sphingosine‐1‐phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin‐sensitive manner
A. Bischoff (2000)
Large unilamellar liposomes with low uptake into the reticuloendothelial system
T. Allen (1987)
Monoclonal antibody covalently coupled to liposomes: specific targeting to cells.
J. Barbet (1981)
Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma
H. S. Tagaram (2010)
Systemic Delivery of Liposomal Short-Chain Ceramide Limits Solid Tumor Growth in Murine Models of Breast Adenocarcinoma
Thomas C. Stover (2005)
Calcium phosphate nanocomposite
M Kester (2008)
Sphingolipid signalling in the cardiovascular system: good, bad or both?
A. Alewijnse (2008)
Biodegradable polymeric nanoparticles based drug delivery systems.
A. Kumari (2010)
Targeted Delivery to Neuroblastoma of Novel siRNA-anti-GD2-liposomes Prepared by Dual Asymmetric Centrifugation and Sterol-Based Post-Insertion Method
Joanna E. Adrian (2011)
Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles
H. Devalapally (2008)
Enriching lipid nanovesicles with short‐chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors
M. Lummel (2011)
Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo.
Brian M Barth (2010)
Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system.
D. Bazile (1995)
Receptor-targeted nanocarriers for therapeutic delivery to cancer
B. Yu (2010)
This paper is referenced by
Preclinical development of a C6-ceramide NanoLiposome, a novel sphingolipid therapeutic
M. Kester (2015)
Molecular Mechanisms of Nanoliposomal C6-ceramide-induced Cell Death in Chronic Lymphocytic Leukemia
Ushma A. Doshi (2015)
Targeting Acid Ceramidase to Improve the Radiosensitivity of Rectal Cancer
R. Clifford (2020)
Bioactive Sphingolipids in Cancer Biology and Therapy
Y. Hannun (2015)
Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer
E. R. Camp (2017)
Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer.
Anita K. Bakrania (2016)
Sphingolipids and lifespan regulation.
Xinhe Huang (2014)
STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia
Ushma A. Doshi (2017)
Chemotherapy and Sphingolipid Metabolism
Ushma A. Doshi (2015)
Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia.
Brian M Barth (2019)
Sphingolipid Mediators of Myocardial Pathology
Anna Kovilakath (2020)
Delivery systems of ceramide in targeted cancer therapy: ceramide alone or in combination with other anti-tumor agents
Y. Ma (2016)